Penumbra, Inc. (NYSE:PEN) Director Sells $3,405,240.00 in Stock

Penumbra, Inc. (NYSE:PEN) Director Arani Bose sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $283.77, for a total transaction of $3,405,240.00. Following the transaction, the director now owns 314,819 shares in the company, valued at $89,336,187.63. The trade was a 3.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Penumbra Price Performance

Shares of PEN stock traded down $6.27 during mid-day trading on Thursday, hitting $268.89. 471,343 shares of the stock were exchanged, compared to its average volume of 395,245. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The firm has a fifty day moving average of $274.49 and a 200 day moving average of $242.13. The company has a market cap of $10.36 billion, a PE ratio of 790.84, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.88 by $0.09. The company had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. Research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Institutional Investors Weigh In On Penumbra

Several institutional investors and hedge funds have recently added to or reduced their stakes in PEN. Quadrant Capital Group LLC lifted its holdings in Penumbra by 6.6% during the fourth quarter. Quadrant Capital Group LLC now owns 632 shares of the company’s stock valued at $150,000 after purchasing an additional 39 shares in the last quarter. Pallas Capital Advisors LLC raised its position in shares of Penumbra by 3.8% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company’s stock worth $263,000 after purchasing an additional 41 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in Penumbra by 11.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock valued at $81,000 after buying an additional 43 shares in the last quarter. Baker Avenue Asset Management LP boosted its holdings in Penumbra by 1.6% in the 4th quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company’s stock worth $791,000 after buying an additional 53 shares during the last quarter. Finally, Pacer Advisors Inc. increased its stake in Penumbra by 1.0% during the 4th quarter. Pacer Advisors Inc. now owns 5,721 shares of the company’s stock worth $1,359,000 after buying an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Truist Financial upped their target price on Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Royal Bank of Canada increased their price objective on Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a report on Wednesday, February 19th. UBS Group raised their price objective on Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Morgan Stanley upped their target price on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 19th. Finally, Robert W. Baird raised their price target on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Penumbra has an average rating of “Moderate Buy” and an average price target of $294.47.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.